Office of Prescription Drug Promotion Untitled Letters

8/29/2024 AbbVie, Inc. UBRELVY (ubrogepant) tablets, for oral use None None 8/1/2024 Mirati Therapeutics Inc., a Bristol Myers Squibb Co. NDA 216340, KRAZATI™ (adagrasib) tablets, for oral use None None 7/17/2024 Kaleo, Inc. NDA 201739, AUVI-Q (epinephrine injection,...

Completed PDUFA VII Deliverables

Publish Draft, Revised, or Final Guidance on Digital Health Technologies Enhancing Use of Digital Health Technologies to Support Drug Development and Review 12/21/2021 Launch Rare Disease Endpoint Advancement Pilot Program Advancing Development of Drugs for Rare...

ANDA Submissions

Docket Number: FDA-2017-D-5670 Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This guidance is intended to explain to applicants how the assessment goals established as part of the Generic Drug User Fee Amendments of 2022 (GDUFA III) apply...